Emcure Pharma Q1 FY27 Results (NSE: EMCURE)
Signal: Growth reaccelerated
The read
Q1 FY27 marks a strong start with revenue accelerating on international momentum, particularly RoW (+44.8%) and Europe (+32.8%). EBITDA margin expanded for the fourth consecutive quarter (to 20.7%) on operating leverage — employee and other expenses grew far slower than revenue. Gross margin compression (‑340bps) is a known trade-off from international mix and is partially offset by the scale benefit. PAT grew 42% with no exceptional drag. The acquisition of Gennova minority stake post-quarter-end simplifies the structure but does not affect current results.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹2,580.45 Cr | 22.8% | 4.5% |
| EBIT | ₹425.06 Cr | 33.9% | |
| Net profit | ₹293.98 Cr | 42.1% | |
| EPS | ₹15.5 | 41.9% | |
| EBIT margin | 20.7% |
P&L walk
Revenue growth was international-led (+34.2% YoY) while domestic subdued (+10.2%). Gross margin compressed 340bps on mix shift (international share rose to 57.6% from 52.7%), but EBITDA margin expanded 90bps as employee cost as % of revenue fell to 15.9% (from 18.7%) and other expenses to 22.9% (from 23.9%). PAT grew 42.1%, helped by zero exceptional items vs ₹35 Mn expense a year ago.
Key positives
- Revenue +22.8% YoY to ₹25,804 Mn, the highest quarterly run-rate in the series.
- International revenue +34.2%, led by RoW +44.8% and Europe +32.8%; international now 57.6% of revenue.
- EBITDA margin expanded 90bps YoY to 20.7%, 4th consecutive quarter of expansion.
- PAT +42.1% YoY to ₹2,940 Mn, aided by zero exceptional items.
- EPS at ₹15.5/-, +41.9% YoY.
Key concerns
- Gross margin compressed 340bps to 58.4% due to business mix shift towards international; if this trend continues, overall margin may remain capped.
- Domestic growth at 10.2% lags the overall company growth; investor focus on whether market share gains sustain.
- Net debt at ₹11,026 Mn (₹1,103 Cr) — debt levels need monitoring as acquisition of Gennova minority stake (₹232 Cr) closed post-quarter.
Research and educational content only. Not investment advice.